Immunohistochemistry in gynecologic pathology

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 2, 2008, Pages 175-180

  Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; CASE REPORT; CONFERENCE PAPER; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; GYNECOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; PATHOLOGY;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; DIAGNOSTIC ERRORS; ENDOMETRIAL NEOPLASMS; FEMALE; GYNECOLOGY; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 38949089323     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999;30:695-700.
2. Byrd-Gloster AL, Khoor A, Glass LF, etal. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol. 2000;31:58-62.
3. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
4. Zamecnik J, Chanova M, Kodet R. Expression of thyroid transcription factor1 in primary brain tumors. J Clin Pathol. 2004;57:1111-1113.
5. Bejarano PA, Baugham RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445-452.
6. Comperat E, Zhang F, Perrotin C, et al. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol. 2005;18:1371-1376.
7. Wieczorek TJ, Pinkus JL, Glickman JN, Pinkus CS. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002;118:911-921.
8. Hecht JL, Pinkus JL, Weinstein LJ, Pinkus GS. The value of thyroid transaction factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol. 2001;116:483-488.
9. Graham AD, Williams ARW, Salter DM. TTF-1 expression in primary ovarian epithelial neoplasia. Histopathology. 2006;48:746-765.
10. Fornasier VL, Paley D. Leiomyosarcoma in bone: primary or secondary? A case report and review of the literature. Skeletal Radiol. 1983;10:147-153.
11. Agoff SN, Grieco VS, Garcia Gown AM. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol. 2001;9:164-169.
12. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 2003;23:729-732.
13. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril. 2004;81:1062-1066.
14. Deavers MT, Silva EG, Euscher ED, Liu J, Broaddus RB, Malpica A. WT1 expression may differentiate mullerian from non-mullerian smooth muscle tumors. Mod Pathol. 2006;19(suppl 1):176A.
15. Kelly TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12:338-341.
16. Paal E, Miettinen M. Retroperitoneal leiomyomas: a clinicopathologic and immunohistochemical study of 56 cases with a comparison to retroperitoneal leiomyosarcomas. Am J Surg Pathol. 2001;25:1355-1363.
17. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol. 1999;12:1001-1009.
18. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology. 2006;48:563-568.
19. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18:20-28.
20. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia and diagnosis. Adv Anat Pathol. 2001;8:83-92.
21. McCluggage WG, Jenkins D. Immunohistochemical staining with p16 may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003;22:231-235.
22. Mikami Y, Kiyokawa T, Hata S, et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and adenoma malignum. Mod Pathol. 2004;17:962-972.
23. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
24. Santos M, Montagut C, Mellado B, et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol. 2004;23:206-214.